SFX by Ex Libris Inc.

Title:	HIV-1 Tat Assembles a Multifunctional Transcription Elongation Complex and Stably Associates with the 7SK snRNP
Source:	Molecular Cell [1097-2765] Sobhian, Bijan yr:2010

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Zolla-Pazner, S. "Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design." Nature Reviews. Immunology 10.7 (2010): 527-535.
description	2.	Thielen, A. "Improved Prediction of HIV‐1 Coreceptor Usage with Sequence Information from the Second Hypervariable Loop of gp120." The Journal of infectious diseases 202.9 (2010): 1435-1443.
description	3.	Eaglstein, William H. "Evidence-Based Medicine, the Research-Practice Gap, and Biases in Medical and Surgical Decision Making in Dermatology." Archives of dermatology 146.10 (2010): 1161-4.
description	4.	Yang, H. "Novel CCR5 antagonists for the treatment of HIV infection: a review of compounds patented in 2006-2008." Expert Opinion on Therapeutic Patents 20.3 (2010): 325-354.
description	5.	Pang, S. "Rapid generation of sequence variation during primary HIV-1 infection." AIDS 6.5 (1992): 453-60.
description	6.	Cardozo, T. "Structural basis for coreceptor selectivity by the HIV type 1 V3 loop." AIDS research and human retroviruses 23.3 (2007): 415-26.
description	7.	Stegenga, H. "Recent NICE Guidance of interest to surgeons." Annals of the Royal College of Surgeons of England 92.3 (2010): 254-256.
description	8.	Monno, L. "Impact of Mutations Outside the V3 Region on Coreceptor Tropism Phenotypically Assessed in Patients Infected with HIV-1 Subtype B." Antimicrobial agents and chemotherapy 55.11 (2011): 5078-5084.
description	9.	Ramesh, R. "Concurrent tolerance allocation using an artificial neural network and continuous ant colony optimisation." International Journal of Design 2.1 (2009): 1-.
description	10.	Funderburg, N. "Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4+ Cell Rises in HIV-Infected Patients." PLoS ONE 5.10 (2010): 1-6.
description	11.	Choudhry, Niteesh K. "How Many "Me-Too" Drugs Is Too Many?" JAMA (Chicago, Ill.) 305.7 (2011): 711-712.
description	12.	Shaw, Michael M. "Extensive variation of human immunodeficiency virus type-1 in vivo." Nature 334.6181 (1988): 440-444.
description	13.	Dunnick, Cory A. "LIFE-THREATENING DERMATOSES AND EMERGENCIES IN DERMATOLOGY." JAMA 303.17 (2010): 1760-1760.
description	14.	Proudfoot, A. "Anti-chemokine small molecule drugs: a promising future?" Expert Opinion on Investigational Drugs 19.3 (2010): 345-55.
description	15.	Neves, Jose D. "Nanotechnology-based systems for the treatment and prevention of HIV/AIDS." Advanced Drug Delivery Reviews 62.4/5 (2009): 458-477.
description	16.	Paul, S. "Specific HIV gp120-cleaving antibodies induced by covalently reactive analog of gp120." The Journal of biological chemistry 278.22 (2003): 20429-20435.
description	17.	Rosen, O. "Molecular switch for alternative conformations of the HIV-1 V3 region:" Proceedings of the National Academy of Sciences of the United States of America 103.38 (2006): 13950-.
description	18.	Bero, E. "Getting research findings into practice: Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings." BMJ 317.7156 (1998): 465-75.
description	19.	Garzino-Demo, A. "Chemokines and defensins as HIV suppressive factors: an evolving story." Current pharmaceutical design 13.2 (2007): 163-72.
description	20.	Zolla-Pazner, S. "Identifying epitopes of HIV-1 that induce protective antibodies." Nature reviews. Immunology 4.3 (2004): 199-210.